Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen

被引:21
作者
Caldas, C
Coelho, VPCV
Rigden, DJ
Neschich, G
Moro, AM
Brígido, MM [1 ]
机构
[1] Univ Brasilia, Dept Biol Celular, BR-70910900 Brasilia, DF, Brazil
[2] Univ Sao Paulo, INCOR, Lab Imunol Transplantes, BR-05403000 Sao Paulo, SP, Brazil
[3] EMBRAPA, CENARGEN, BR-70770900 Brasilia, DF, Brazil
[4] Inst Butantan, BR-05503900 Sao Paulo, SP, Brazil
来源
PROTEIN ENGINEERING | 2000年 / 13卷 / 05期
关键词
CD18; humanization; monoclonal antibody; Pichia pastoris; scFV;
D O I
10.1093/protein/13.5.353
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The 6.7 murine monoclonal antibody (mAb) recognizes the human CD18 antigen and is therefore of interest as an anti-inflammatory agent. The 6.7 heavy variable chain (VH) was humanized using the closest human germline sequence as the template on to which to graft the murine complementary determining regions (CDRs), Two versions were proposed, one in which the residue proline 45 of the murine form was maintained and another in which this framework residue was changed to the leucine found in the human sequence. These VH humanized versions were expressed in the yeast Pichia pastoris as hemi-humanized single-chain Fv (scFvs), with the VL from the murine antibody. The scFv from the murine antibody was also expressed. The binding activities of the murine and both hemi-humanized scFvs were determined by how cytometry analysis. All the constructions were able to recognize human lymphocytes harboring CD18, indicating successful humanization with transfer of the original binding capability. Some differences between the two hemi-humanized versions were observed. The method used was simple and straightforward, with no need for refined structural analyses and could be used for the humanization of other antibodies.
引用
收藏
页码:353 / 360
页数:8
相关论文
共 55 条
[1]   Gapped BLAST and PSI-BLAST: a new generation of protein database search programs [J].
Altschul, SF ;
Madden, TL ;
Schaffer, AA ;
Zhang, JH ;
Zhang, Z ;
Miller, W ;
Lipman, DJ .
NUCLEIC ACIDS RESEARCH, 1997, 25 (17) :3389-3402
[2]   TOLERANCE TO RAT MONOCLONAL-ANTIBODIES - IMPLICATIONS FOR SEROTHERAPY [J].
BENJAMIN, RJ ;
COBBOLD, SP ;
CLARK, MR ;
WALDMANN, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 163 (06) :1539-1552
[3]  
BRIGIDO MM, 1993, J IMMUNOL, V150, P469
[4]  
BRIGIDO MM, 1992, THESIS U SAO PAULO
[5]   THE IMMUNOGENICITY OF CHIMERIC ANTIBODIES [J].
BRUGGEMANN, M ;
WINTER, G ;
WALDMANN, H ;
NEUBERGER, MS .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (06) :2153-2157
[6]   CONFORMATIONS OF IMMUNOGLOBULIN HYPERVARIABLE REGIONS [J].
CHOTHIA, C ;
LESK, AM ;
TRAMONTANO, A ;
LEVITT, M ;
SMITHGILL, SJ ;
AIR, G ;
SHERIFF, S ;
PADLAN, EA ;
DAVIES, D ;
TULIP, WR ;
COLMAN, PM ;
SPINELLI, S ;
ALZARI, PM ;
POLJAK, RJ .
NATURE, 1989, 342 (6252) :877-883
[7]   HUMANIZED ANTIBODIES FOR ANTIVIRAL THERAPY [J].
CO, MS ;
DESCHAMPS, M ;
WHITLEY, RJ ;
QUEEN, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (07) :2869-2873
[8]  
Co MS, 1996, CANCER RES, V56, P1118
[9]  
COLOMA MJ, 1991, BIOTECHNIQUES, V11, P152
[10]  
COUTO JR, 1995, CANCER RES, V55, pS5973